RESTORE has dosed its first participant, moving NVG-291 into a registrational Phase 3 test. A large unmet need and June cash support the thesis, while efficacy replication, enrollment, accounting controls and future dilution remain decisive. The $3.05 risk-adjusted fair value is unchanged from the earlier assessment and implies 114.8% upside from the $1.42 analysis close; the $0.75 bear case entails substantial capital loss.
Ten explicit product-cash-flow years, 2030–39; no terminal perpetuity or non-U.S. sales. Discounting probability-weighted annual revenue at 12% gives the lead contribution shown above. The gap between the market price and the 60% success assumption in the base model reflects skepticism about small-study replication, uptake and funding; share-price moves alone are not evidence of clinical progress. A separate 2034 terminal EV check — $700m sales × SUPN-derived 2.0× × 60%, discounted eight years, plus cash and options less costs and warrant dilution — gives $3.30/share, 8% above base. The implied terminal EV/peak-sales multiple is 2.0×, within 1% of the 1.98× SUPN anchor. The base value is about 70% below the $10.33 dated aggregate analyst target because it uses ~2.1% annual penetration, excludes non-U.S. revenue and assigns little to other indications. A ±10-point success shift moves the basic-share model by about $0.48/share; changing the product cash-flow scale 2× changes fair value by far more than 30%. Scenario weights illustrate outcomes and are not reapplied to the already risk-adjusted base asset. ⚠️ Not investment advice. The previously published $3.05 fair value is unchanged: the amended statements altered non-cash accounting but not cash, cash flows, shares or the clinical assumptions in this model. The share-price decline from $1.62 to $1.42 expanded the indicated upside from 88% to 114.8%; it does not reduce trial risk.
| Component | Assumption | USD/share |
|---|---|---|
| NVG-291 in chronic tetraplegia | 2026 rNPV: 2030–39 revenue $80m→$700m; 30% product cash margin; 12% discount; 60% success × $515.6m un-risked PV / 107.523m shares | +2.877 |
| Reported cash | $61.1m at June 30, 2026 / 107.523m shares; no interest-bearing debt | +0.568 |
| NVG-291 other indications | 10% option probability × $60m illustrative NPV / 107.523m shares | +0.056 |
| NVG-300 research program | 5.5% preclinical probability × $60m illustrative NPV / 107.523m shares | +0.031 |
| Remaining RESTORE expenditure | Analyst-estimated $25.5m present value after June 30, 2026 / 107.523m shares | -0.237 |
| Future corporate and filing costs | Analyst-estimated $15m present value outside product margin / 107.523m shares | -0.140 |
| In-the-money warrant dilution | (Pre-exercise equity + $22.47m strike cash) / (107.523m + 10.982m shares) minus $3.155/sh. basic value | -0.103 |
| FV base case | Arithmetic sum of the per-share components above: $3.052; rounded headline $3.05 | +3.052 |
34.982m warrants were outstanding at August 12. The 24m May warrants strike at $3.68 and mature in 2031; 10.982m older warrants have lower strikes, modeled in base value. The 2026 ATM had sold no shares by August 13. The model assigns no extra value to insider transactions or litigation outcomes. Q2 2026 amended MD&A — SEC · Q2 2026 amended statements — SEC · NGEN short interest and valuation — Stock Analysis.
| Item (C$ million) | FY2023 | FY2024 | FY2025 restated | 1H2026 restated |
|---|---|---|---|---|
| Product revenue | 0 | 0 | 0 | 0 |
| Research and development | 8.046 | 15.505 | 13.466 | 12.576 |
| General and administrative | 9.730 | 8.161 | 9.822 | 6.543 |
| Net income (loss) | (22.382) | (23.665) | (44.214) | +8.877 |
| End-of-period cash | 11.660 | 17.267 | 22.070 | 86.790 |
| Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
| Product revenue | 0 | 0 | 0 | 0 | 0 |
| R&D | 2.624 | 4.265 | 3.532 | 4.781 | 7.795 |
| G&A | 3.298 | 1.296 | 2.590 | 2.476 | 4.067 |
| Net income (loss) | (8.999) | (4.718) | (26.492) | (1.925) | +10.803 |
The company release expects cash to fund operations through the 1H2028 RESTORE readout. The formal MD&A states cash covers the ensuing 12 months and says later filings and trials require more capital. These statements have different horizons; monitor updated budgets. NervGen Q2 2026 release · Q2 2026 amended MD&A — SEC.
Business model — NVG-291 in chronic tetraplegia
RESTORE is randomized, double-blind and placebo-controlled, with roughly 150 participants across U.S. and Canadian sites. Its primary endpoint is GRASSP Quantitative Prehension, a hand-function measure after 12 weeks of treatment. FDA alignment concerns trial design and does not pre-approve NVG-291 or guarantee statistical success. RESTORE first participant dosed — NervGen · End-of-Phase-2 FDA alignment — NervGen .
The earlier Phase 1b/2a chronic cohort enrolled about 20 people. Reported GRASSP Quantitative Prehension change was +3.7 on treatment versus +0.4 on placebo in a small sample. The publicized 2.6× figure described GRASSP Total Score improvement at week 16, not RESTORE’s primary endpoint. The small trial provides a rationale, while replication remains the central investment risk. End-of-Phase-2 FDA alignment — NervGen · Clinical data and risk disclosure — SEC prospectus .
NervGen’s May 2026 presentation estimates about 149,000 U.S. adults with chronic incomplete tetraplegia and illustrates a $150k–$300k price per course. These are company estimates, not an approved addressable market or a payer price. The base model treats about 3,100 U.S. patients annually at peak. Other neurologic indications and NVG-300 are early and receive less than 3% of base fair value combined. May 2026 corporate presentation — NervGen, archived copy .
Legal, regulatory and risk analysis
SWOT analysis
- +RESTORE is dosing after FDA design alignment.
- +Q2 cash was C$86.8m / US$61.1m.
- +High unmet need in chronic cervical SCI.
- +Fast Track and EMA orphan designations.
- −No approved therapy or product revenue.
- −Small efficacy dataset before Phase 3.
- −107.52m shares versus 79.65m at FY2025 end.
- −Amended filings expose reporting-control risk despite unchanged cash.
- →A positive registrational endpoint could validate a new therapeutic category.
- →The U.S. addressable population is large relative to modeled 2.1% penetration.
- →Partnerships could reduce commercialization funding needs.
- →Other indications remain low-weight option value.
- !Phase 3 effect may fail to replicate.
- !Safety or regulatory constraints may narrow the label.
- !ATM issuance and warrants may dilute holders.
- !Price and reimbursement could fall below assumptions.
Summary by assessment area
- RESTORE first participant dosed October 12, 2026.
- The Phase 3 endpoint must replicate a small earlier signal.
- Risk-adjusted base fair value $3.05 versus $1.42 close, +114.8%.
- Bull $6.77; bear $0.75. Peak uptake and success probability dominate.
- C$86.8m cash at June 30; 34.98m warrants outstanding at August 12.
- Restated figures, cash use and ATM utilization need monitoring.
Sources: NGEN 22 Oct price — Yahoo Finance , NGEN price history — ChartExchange , NGEN 52-week range — Investing.com , NervGen Q2 2026 release , Q2 2026 amended MD&A — SEC , Q2 2026 amended statements — SEC , FY2025 amended statements — SEC , FY2023 statements — SEC , RESTORE first participant dosed — NervGen , End-of-Phase-2 FDA alignment — NervGen , Clinical data and risk disclosure — SEC prospectus , May 2026 corporate presentation — NervGen, archived copy , May 2026 $60m offering — NervGen , September 2026 restatement announcement — NervGen , NGEN short interest and valuation — Stock Analysis , ALKS valuation multiples — Stock Analysis , SUPN valuation multiples — Stock Analysis , AXSM valuation multiples — Stock Analysis , Clinical development success rates — BIO , TSXV delisting — SEC filing · September 2026 short interest and float — ChartMill . Market data — last verified close 2026-10-22: NGEN ~$1.42, market cap ~$152.7m, 52W range $1.42–$6.30, 107.523m shares outstanding. Short interest: 5.832m shares at 2026-09-30, 5.42% of outstanding (6.53% of ChartMill float). Yahoo Finance and Investing.com agree on the close. The June 2026 cash balance is C$86.790m / US$61.1m as reported by the issuer; the October 16 restatement did not change cash or cash flows. Scenario probabilities and product prices are analyst assumptions. This document is for informational purposes only and does not constitute financial or investment advice.